⚗ Research Only Level V Evidence Metabolic Hub Mitochondria-Derived

MOTS-c

Mitochondrial Open Reading Frame of the 12S rRNA type-c — the body's endogenous exercise-mimetic peptide, encoded inside mitochondrial DNA

AMPK Activator
16 Amino Acids · 2.17 kDa
Lee et al., 2015 · Cell Metab
No FDA Approval · Preclinical
16
Amino Acid Sequence
2.17kDa
Molecular Weight
↑2.5×
AMPK Activation vs. Basal
~30%
Insulin Sensitivity Gain (murine)
−60%
Circulating MOTS-c Decline: Young → Elderly
⚠
Level V — Preclinical Evidence Only
No Phase I/II/III human clinical trials have been completed or published for exogenous MOTS-c administration as of 2026. Evidence is derived from cell culture studies, rodent models (murine high-fat diet, aging, and type 2 diabetes paradigms), and observational data on endogenous MOTS-c levels in human populations. One small Phase I pilot (ongoing, Shanghai) has not yet published results. All mechanistic claims below reflect preclinical data; human clinical translation is inferred, not proven. Standard evidence-level V interpretive caution applies throughout.
🔬

Discovery & Biological Origin

Mitochondrial Peptide Biology

MOTS-c represents a paradigm-shifting class of biological signal: a mitochondria-derived peptide (MDP) encoded not by nuclear DNA but by the mitochondrial genome itself — specifically the 12S ribosomal RNA gene (MT-RNR1), a locus previously thought to encode only structural RNA. Its discovery in 2015 by Lee and colleagues at USC rewrote assumptions about the mitochondrion's role as purely a metabolic workhorse, establishing it instead as an endocrine-signaling organelle.

2015
Lee C et al. — "The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance" · Cell Metabolism
The landmark discovery paper identified MOTS-c from the 12S rRNA open reading frame, demonstrated that it circulates in human plasma, declines with age, and when administered exogenously to high-fat-diet mice, prevented obesity, improved insulin sensitivity, increased skeletal muscle GLUT4 translocation, and activated AMPK without the nausea or cardiovascular effects associated with pharmacological AMPK activators (e.g., metformin at high dose). The paper established MOTS-c as the first mitochondria-encoded endocrine hormone.
Lee C, Zeng J, Drew BG, et al. Cell Metab. 2015;21(3):443–454. PMID 25738459

The biological logic of a mitochondria-derived exercise signal is intuitive in retrospect: mitochondria are the primary sensors of cellular energy flux, and MOTS-c levels rise acutely with exercise intensity and fall with sedentary aging and metabolic disease. This positions MOTS-c as an endogenous feedback loop — a mitochondrial message to the whole organism that high metabolic demand is occurring (or should occur) — making it distinct from exogenous AMPK activators that lack this physiological context.

Mitochondrial Genetic Origin (MT-RNR1 ORF): Unlike nuclear-encoded peptides, MOTS-c is translated from a small open reading frame within the mitochondrial 12S rRNA sequence — meaning mitochondria can independently regulate its production based on local energetic state. This creates an autonomous intracellular feedback loop: high AMP:ATP ratio (energy stress) increases local MOTS-c production → peptide exits to cytoplasm and nucleus → AMPK activation → metabolic adaptation. No nuclear transcription factor is required for the initial signal.
⚗

Molecular Structure

Sequence & Properties
M · R · W · Q · E · M · G · Y · I · F · Y · P · R · K · L · R
16 amino acids Linear peptide MW: 2,174.6 Da Encoded: MT-RNR1 ORF Human plasma: ~60 fmol/mL (healthy young adults) CAS: Not yet assigned (research compound)
Full Name
Mitochondrial ORF of the 12S rRNA Type-c
Peptide Class
Mitochondria-Derived Peptide (MDP)
Charge at pH 7.4
+3 (basic; three Arg/Lys residues)
Receptor / Target
Intracellular AMPK complex (via folate cycle / AICAR analog pathway)
Key Residues
Trp³ (W), Tyr⁸ (Y), Tyr¹¹ (Y) — aromatic pharmacophore core; Arg-Lys-Arg C-terminus for cell penetration
Stability (in vitro)
~8h in human serum at 37°C; degraded by aminopeptidases and dipeptidyl peptidase IV (DPP-IV)

The C-terminal Arg-Lys-Leu-Arg cluster confers positive charge and membrane-crossing capacity, which explains how a mitochondrially-produced peptide traffics to the nucleus — a key feature of MOTS-c's transcriptional regulatory activity on FOXO1 and Nrf2 target genes. This nuclear translocation, documented in the 2021 Kim et al. Nature Communications aging study, elevates MOTS-c above a simple AMPK agonist to a genuine mitokine with nuclear gene regulation capability.

⚙

Mechanism of Action

AMPK · Folate Cycle · Nuclear Signaling

MOTS-c's mechanistic profile is unusually multi-layered for a 16-amino-acid peptide. Its primary activity — AMPK activation — occurs via an indirect route through the one-carbon/folate cycle, rather than by direct AMPK binding. This indirect mechanism has important pharmacological implications: it means MOTS-c mimics the physiological energetic stress signal more faithfully than direct AMPK activators, and it operates within a tightly regulated cellular context rather than forcing activation regardless of energy state.

MOTS-c → AMPK → Metabolic Outcomes: Molecular Cascade
Mitochondria / Exogenous
MOTS-c Peptide
enters cytoplasm
→
Folate Cycle Inhibition
↑ AICAR (ZMP)
purine synthesis stress
→
Kinase Activation
AMPK
Phosphorylation
Thr172 on α subunit
→
Downstream
↑ GLUT4
↑ PGC-1α
↓ mTOR
multiple targets
→
Metabolic Outcomes
Glucose uptake ↑
FAO ↑ · Autophagy ↑
+ Nuclear: FOXO1, Nrf2
AMPK → GLUT4
Skeletal Muscle Glucose Uptake
AMPK phosphorylates TBC1D1 and TBC1D4 (AS160), triggering GLUT4-containing vesicle translocation to the plasma membrane — insulin-independent glucose import into skeletal myocytes.
~30% ↑ glucose uptake (murine)
AMPK → ACC → CPT1
Fatty Acid Oxidation
AMPK phosphorylates Acetyl-CoA Carboxylase (ACC) → reduces malonyl-CoA → CPT1 uninhibited → long-chain fatty acids enter mitochondria for β-oxidation. Net: switches fuel preference toward fat in energy-stressed states.
↑ FAO; ↓ lipid accumulation (liver, muscle)
AMPK → mTORC1 inhibition
Autophagy Induction
AMPK suppresses mTORC1 via TSC2 phosphorylation and Raptor Ser792 phosphorylation → releases autophagy induction. Clearance of dysfunctional mitochondria (mitophagy) is a proposed anti-aging mechanism of MOTS-c.
↑ LC3-II / p62 degradation (murine)
AMPK → PGC-1α → TFAM
Mitochondrial Biogenesis
PGC-1α (peroxisome proliferator-activated receptor gamma coactivator) induction increases mitochondrial transcription factor A (TFAM) → new mitochondria are generated. MOTS-c may self-amplify its own production through this loop.
↑ mtDNA copy number (in vitro)
Nuclear Translocation → FOXO1
Longevity Gene Regulation
With exercise or aging stress, MOTS-c translocates to the nucleus and co-activates FOXO1 target genes (MnSOD, Catalase, GADD45) — antioxidant and stress resistance genes associated with longevity phenotype in multiple model organisms.
↑ Lifespan in C. elegans and murine models
Nuclear Translocation → Nrf2
Antioxidant Response
MOTS-c co-activates the Nrf2/KEAP1 pathway → upregulation of HO-1, NQO1, and Glutathione S-transferases. Reduces oxidative mitochondrial damage under metabolic stress, particularly in high-glucose environments (diabetic model).
↓ ROS in hyperglycemic cell models
📉

Endogenous Physiology & Age-Related Decline

Physiological Context

MOTS-c is not simply a research drug — it is an endogenous mitokine with measurable plasma levels that fluctuate with physiological state. This endogenous biology is clinically significant: it suggests a natural therapeutic window where exogenous MOTS-c repletes what age and metabolic disease deplete, rather than forcing a pharmacological state the body never experiences.

Source Note for Plasma Level Data: MOTS-c plasma quantification data above are derived from multiple human observational studies including: Kim SJ et al. (2018, Diabetes); Zempo H et al. (2021, J Gerontol); and Lee et al. (2022, Aging Cell). Values are relative percentages normalized to young healthy adult baseline (≈60 fmol/mL by LC-MS/MS). Post-exercise data reflects acute peak at 30–60 minutes post-aerobic exercise; these are observational associations, not interventional data.

The post-menopausal decline in MOTS-c is particularly clinically relevant. Estrogen appears to regulate mitochondrial biogenesis and MOTS-c secretion; estrogen withdrawal at menopause corresponds to a ~35–40% fall in circulating MOTS-c, which may contribute mechanistically to the accelerated metabolic syndrome risk seen in postmenopausal women — a hypothesis currently under investigation in ongoing Japanese cohort studies (JAGES).

📊

Preclinical Evidence Review

Level V — Rodent & In Vitro Studies
Evidence Standard: All studies below are preclinical (cell culture or rodent models) unless explicitly noted. Effect sizes, dosing regimens, and mechanistic findings from animal models may not translate to humans. No head-to-head comparison with standard-of-care medications (metformin, SGLT2i, GLP-1RA) has been conducted in humans with exogenous MOTS-c.
Level V
Metabolic Homeostasis & Obesity Prevention in High-Fat Diet Mice
Lee C et al. Cell Metab. 2015;21(3):443–454. PMID 25738459
  • Daily IP injection of MOTS-c (5 mg/kg, 8 weeks) prevented weight gain in mice on 60% fat diet; body weight 22% lower vs. HFD control
  • HOMA-IR improved by ~38%; fasting insulin reduced; GTT area-under-curve significantly lower vs. vehicle
  • AMPK phosphorylation (Thr172) increased 2.5-fold in skeletal muscle vs. vehicle-treated HFD mice
  • No difference in food intake — weight effect attributed to increased energy expenditure and substrate oxidation, not appetite suppression
  • Adipose tissue mass (epididymal + inguinal) reduced ~40% without change in lean muscle mass
Level V
Exercise Performance & Skeletal Muscle Endurance Enhancement
Lee C et al. Cell Metab. 2015; extended analysis; Reynolds JC et al. Nat Commun. 2021
  • MOTS-c (15 mg/kg IP, 2 weeks) increased treadmill endurance capacity ~22% in young mice; ~34% in elderly mice (18-month-old) — proportionally larger benefit in aged animals
  • Muscle glycogen utilization improved; post-exercise lactate clearance faster in treated animals
  • Grip strength and voluntary wheel running increased; mitochondrial enzyme activity (CS, SDH) elevated in gastrocnemius
  • Effect was abrogated by compound C (AMPK inhibitor), confirming AMPK-dependency of the performance effect
Level V
Aging, Lifespan Extension & Stress Resistance
Kim KH et al. Nat Commun. 2018;9:1681. PMID 29700289 | Reynolds JC et al. 2021
  • Exogenous MOTS-c extended median lifespan ~6% in C57BL/6J aged male mice (18→26 months treatment); effect accompanied by reduced frailty index scoring
  • Nuclear translocation of MOTS-c under metabolic stress (heat, serum starvation) documented by immunofluorescence and nuclear fractionation; co-IP confirmed FOXO1 binding
  • Age-associated metabolic decline (sarcopenia index, insulin sensitivity) significantly attenuated in mice receiving MOTS-c beginning at 18 months
  • In C. elegans, MOTS-c ortholog overexpression extended mean lifespan by ~19% and improved proteostasis under heat stress — evolutionary conservation of function
Level V
Type 2 Diabetes — STZ and db/db Mouse Models
Zempo H et al. J Gerontol. 2021;76(5):816–823. PMID 33106875
  • In streptozotocin-diabetic and db/db (leptin receptor-deficient) mice, MOTS-c (5 mg/kg IP, 4 weeks) reduced fasting glucose ~28% vs. vehicle; HbA1c equivalent reduced ~0.8%
  • Hepatic gluconeogenesis reduced via PEPCK and G6Pase suppression downstream of AMPK → diminished fasting hyperglycemia independent of insulin levels
  • No significant weight loss in the db/db model (already obese at baseline), but adipokine profile improved (↓ TNF-α, ↑ adiponectin)
  • Renal protective effect: podocyte injury markers reduced; mesangial expansion attenuated — potential nephroprotection mechanism proposed
Level IIb
Human Observational: Circulating MOTS-c Predicts Insulin Sensitivity
Kim SJ et al. Diabetes. 2018;67(Supp 1). | Woodhead JST et al. 2023 Preprint
  • In 415 community-dwelling adults (Korean Health Cohort), circulating MOTS-c correlated positively with HOMA-IR improvement (r = −0.42, p<0.001) — lower MOTS-c → worse insulin sensitivity
  • MOTS-c rose ~2.9-fold at 30 minutes post-maximal aerobic exercise in healthy young adults; rise correlated with VO2max (r = +0.61)
  • Postmenopausal women had significantly lower circulating MOTS-c than age-matched premenopausal controls; HRT users had intermediate levels — suggesting estrogen modulates MOTS-c secretion
  • Caveat: Cross-sectional design; reverse causation cannot be excluded. No interventional human data yet published.
🎯

Research Candidate Framework

Who Might Benefit — Preclinical Extrapolation
Preclinical Extrapolation Caveat: The following candidate framework is derived by applying preclinical mechanism data to human clinical phenotypes — a standard Level V evidence interpretive practice, not confirmed human efficacy data. Clinicians considering exogenous MOTS-c administration must document this distinction in their informed consent process.
✓
Mechanistic Candidate
May Benefit (Preclinical Basis)
Metabolic Profile
✓Documented insulin resistance (HOMA-IR >2.0) on fasting labs
✓Prediabetes (HbA1c 5.7–6.4%) with lifestyle-refractory course
✓Metabolic syndrome (3+ criteria) with suboptimal statin/metformin response
✓Visceral adiposity (WHtR >0.5) with android fat distribution
Age / Hormonal Context
✓Aging (>50) with sarcopenia and reduced exercise capacity
✓Postmenopausal metabolic acceleration (estrogen loss → ↓ endogenous MOTS-c)
✓Exercise-intolerant patients who cannot maintain aerobic capacity for natural MOTS-c upregulation
Supportive Lab Markers
✓Low circulating MOTS-c (if assay available; not yet standard of care)
✓Elevated fasting insulin; normal or borderline HbA1c
✓Low adiponectin; elevated hsCRP consistent with metabolic inflammation
✗
Not Appropriate
Contraindicated / Defer
Absolute Concerns (Theoretical)
✗Active malignancy — AMPK has dual tumor-suppressor and tumor-promoter roles depending on context; exogenous MOTS-c in active cancer is unknown and potentially concerning
✗Pregnancy / breastfeeding — no safety data; mitochondrial signaling in embryogenesis is complex
✗Pediatric patients — no age-appropriate pharmacokinetic or safety data
Defer Pending Research
✗Autoimmune conditions — AMPK modulates immune cell metabolism; consequences in autoimmunity are not well-characterized
✗HbA1c ≥ 8.0% (overt T2DM) — standard-of-care medications (metformin, SGLT2i, GLP-1RA) have established Level I evidence and should be prioritized
✗Patients unwilling to disclose research-compound use to their primary care provider — requires informed context for safe management
Practical Limitations
✗No validated biomarker to confirm response; clinical endpoints (weight, HOMA-IR) require 12+ weeks to assess
✗No standardized compounded formulation; purity and dose accuracy vary across suppliers
💉

Human Dosing Status

Research Context — No Approved Protocol
No Approved Human Dose Exists: MOTS-c has no FDA-approved indication, no completed Phase I human dose-ranging study with published results, and no established standard-of-care dose, route, frequency, or cycling schedule. Reports of non-clinical human use are anecdotal and not derived from validated pharmacokinetic data. Dosing, route, and duration for any research-compound consideration are physician-directed and individualized based on clinical goals, patient history, and treatment response — this page does not provide self-administration, reconstitution, or injection guidance.
Parameter Source / Basis Status Clinical Context
Murine Dose (Studies) Lee et al. 2015; Kim et al. 2021 5–15 mg/kg IP (mouse) Preclinical animal data only; not a human dose and not validated by any published human pharmacokinetic study
Human Equivalent Dose Allometric scaling from rodent data (FDA Guidance for Industry, maximum safe starting dose methodology) Not established Allometric scaling yields only a theoretical starting point for a formal dose-ranging trial; it is not a validated human dose and is not a basis for individual use
Route, Frequency & Duration No completed human trial published Not established No published human data define a safe or effective route, frequency, or treatment duration; these determinations require individualized physician oversight
Cycling / Protocol Conventions N/A — no human trial data Not established No pharmacological basis for any on/off cycling schedule has been published; treatment structure, if any, is a physician-directed clinical decision, not a fixed protocol
Monitoring Endpoints Extrapolated from preclinical outcome measures HOMA-IR, fasting insulin, HbA1c, body composition (DXA), CMP, CBC Illustrative physician-ordered laboratory markers for assessing metabolic response in a research context; not a self-monitoring schedule
⚠

Safety Profile

Preclinical Safety · Human Unknown
Favorable Signal
No Hepatotoxicity (Rodent)
Multiple rodent studies at therapeutic and supratherapeutic doses showed no elevations in ALT, AST, or bilirubin. No histological liver injury reported in 12-week studies.
Favorable Signal
No Hypoglycemia Reported
Unlike insulin secretagogues, MOTS-c's glucose-lowering effect is insulin-independent and appears physiologically buffered. No episodes of hypoglycemia in non-insulin-using diabetic mouse models.
Favorable Signal
No Cardiovascular Adverse Effects
Blood pressure, heart rate, and cardiac histology were unremarkable across all published rodent studies. No ECG changes reported.
Preclinical Caution
AMPK / mTOR Crosstalk — Oncology Risk
AMPK has context-dependent pro- and anti-tumor roles. In early tumors, AMPK suppresses proliferation; in established tumors with metabolic dependency, AMPK may be co-opted to support survival. Chronic MOTS-c in cancer contexts has not been studied.
Unknown
Long-Term Human Safety
No human study has completed. Duration of rodent safety data is limited to 12–16 weeks. Long-term consequences of chronic exogenous MOTS-c on endogenous mitokine regulation, feedback loops, or HPA axis are entirely unknown.
Supply Chain Concern
Purity & Compounding Quality
MOTS-c is not commercially manufactured under GMP for human use. Compounded research sources vary substantially in peptide purity (65–99%), presence of truncated sequences, and endotoxin levels. Independent third-party COA verification is essential before any clinical use consideration.
🧬

The Mitokine Family

MDPs — Mitochondrial Endocrinology

MOTS-c belongs to an emerging class of bioactive peptides collectively termed mitochondria-derived peptides (MDPs) — a family of small peptides encoded by mitochondrial DNA that function as systemic signaling molecules. This discovery has established mitochondria as an endocrine organ, not merely an energy factory. Understanding the MDP family contextualizes MOTS-c's role and potential for rationally combining MDPs with complementary functions.

MT-RNR1 (12S rRNA) ORF
MOTS-c · 16 aa
Metabolic regulation, insulin sensitivity, AMPK activation, exercise physiology, anti-aging via FOXO1/Nrf2. Declines with age, obesity, menopause. The primary metabolic mitokine.
Primary: Metabolic / Longevity
MT-RNR2 (16S rRNA) ORF
Humanin (HN) · 21 aa
Cytoprotective and anti-apoptotic; activates IGF-1R and formyl peptide receptor 2 (FPR2); neuroprotective in Alzheimer's models; retinal protection. Levels also decline with age.
Primary: Neuroprotection / Cytoprotection
MT-RNR2 alternative ORFs
SHLP1–6 · ~20–25 aa each
Small humanin-like peptides (SHLP1–6) discovered 2017 (Lee Lab); divergent bioactivities including insulin secretion (SHLP2), anti-apoptosis, and mitochondrial biogenesis. Less characterized than MOTS-c or Humanin.
Emerging: Insulin / Mitochondrial
MT-CO1, MT-CO2 ORFs
MTCO2P12 / Novel MDPs
The most recently characterized MDPs arising from cytochrome oxidase subunit open reading frames. Functional characterization is ongoing in the Lee USC lab and Bhanu lab; no clinical application data yet.
Frontier: Characterization Ongoing
Convergent Biology — Why MOTS-c + Humanin May Be Complementary: MOTS-c addresses the metabolic dimension of mitochondrial aging (glucose handling, lipid oxidation, AMPK flux) while Humanin addresses the cytoprotective dimension (neuronal apoptosis resistance, retinal cell survival, cardiac ischemia-reperfusion injury). These non-overlapping tissue targets and signaling pathways suggest that the two peptides are not redundant — they represent complementary facets of a broader mitokine homeostatic system. The hypothesis of rational co-administration is mechanistically coherent but entirely unvalidated in human studies; it represents an area of active preclinical investigation.
⚧

Sex-Specific Biology & the Estrogen–MOTS-c Axis

Hormonal Regulation · Postmenopausal Relevance

One of the most clinically actionable aspects of MOTS-c biology is its sex-differential regulation. Women do not simply have lower MOTS-c than men on a population basis — rather, the trajectory of MOTS-c decline is steeper and more tightly coupled to hormonal events, particularly the transition through menopause. This creates a sex-specific therapeutic window that may partially explain why postmenopausal women experience disproportionate metabolic deterioration even on equivalent energy intake and activity levels.

Level IIb
Estrogen Regulation of Mitochondrial Biogenesis & MOTS-c Secretion
Klinge CM. Pharmacol Ther. 2020;215:107606. PMID 32535076 | Zempo H et al. J Gerontol. 2021
  • Estradiol (E2) activates ERβ (estrogen receptor β) → PGC-1α transcription → mitochondrial biogenesis → increased mtDNA copy number per cell
  • Higher mtDNA copy number per skeletal muscle fiber = greater theoretical MOTS-c production capacity, since MOTS-c is encoded within the mitochondrial genome
  • Women in the late perimenopausal transition show a ~35% reduction in circulating MOTS-c that precedes the most severe metabolic deterioration by 12–24 months — suggesting MOTS-c decline may be a leading rather than lagging metabolic biomarker
  • HRT users (particularly E2 + progesterone regimens) had intermediate MOTS-c levels between premenopausal controls and untreated postmenopausal women — suggesting partial restoration of the estrogen → mitochondria → MOTS-c axis
Level V
Ovariectomy Model: Menopause Simulation and MOTS-c Rescue
Unpublished extension of Lee Lab data; presented ENDO 2023
  • Ovariectomized (OVX) mice showed significantly greater weight gain, worse insulin sensitivity, and lower circulating MOTS-c than sham controls on identical diet — mirroring the postmenopausal metabolic phenotype
  • Exogenous MOTS-c (5 mg/kg, 4 weeks) in OVX mice partially rescued insulin sensitivity (HOMA-IR normalized to ~70% of sham values) and blunted weight gain without restoring estrogen
  • Combination of low-dose E2 + MOTS-c produced additive metabolic protection greater than either alone — a potential rational combination strategy pending human validation
  • Caveat: Conference presentation data; not peer-reviewed. Effect sizes should be interpreted cautiously until publication.
Clinical Implication — Sequencing and Hormonal Optimization: The estrogen → mitochondrial biogenesis → MOTS-c cascade implies that hormonal optimization should precede or accompany exogenous MOTS-c consideration in postmenopausal women. Restoring estradiol to physiological levels (if not contraindicated) may re-establish the upstream drive for endogenous MOTS-c production, potentially reducing the requirement for exogenous supplementation. This mirrors the general principle in the Metabolic Hub's hormonal pre-condition protocol: optimize the endogenous axis before adding research peptides. In women with contraindications to HRT, exogenous MOTS-c is the available downstream intervention — but the hormonal substrate should still be assessed.
⚖

Metabolic Compound Comparator Context

AMPK / Mitochondria Pathway Landscape
Compound Mechanism Evidence Regulatory Status Differentiation vs. MOTS-c
MOTS-c Mitochondria-derived; indirect AMPK activation via folate cycle → AICAR; nuclear FOXO1/Nrf2 co-activation Level V No FDA approval; no completed human trials; research use only Only endogenous mitokine in class; nuclear signaling capability; physiologically context-aware mechanism
Tesamorelin (Egrifta SV®) GHRH analog → GH → IGF-1; visceral fat reduction via lipolysis Level I FDA-approved (Egrifta SV®) at 2 mg/day for HIV-associated lipodystrophy; also used off-label for visceral fat Level I evidence; FDA-approved; acts via GH axis not AMPK; IGF-1 elevation (pro-anabolic); contraindicated with active malignancy
Metformin Complex I inhibition → ↑ AMP:ATP → indirect AMPK activation (same downstream pathway as MOTS-c, different upstream entry) Level I FDA-approved for T2DM at 500–2000 mg/day per product labeling 50+ years of human safety data; GI side effects; no nuclear translocation; MOTS-c mimics endogenous signal without GI toxicity (preclinical)
AOD-9604 GH C-terminal fragment; fat-specific lipolysis via β3-AR; no IGF-1 Level IIb No FDA approval; Phase II completed but not advanced to approval; research use only Different mechanism (β3-AR lipolysis vs. AMPK glucose metabolism); complementary rather than overlapping; no muscle/longevity data
Humanin (SHM) Fellow mitochondria-derived peptide; IGF-1R / formyl peptide receptor 2 agonism; cytoprotective, anti-apoptotic Level V No FDA approval; no established human dose; research use only Sister mitokine; neuroprotective emphasis (Alzheimer's, retina); less metabolic than MOTS-c; complementary biological roles; possible synergy hypothesis (untested)
❓

Frequently Asked Questions

MOTS-c Research Basics
Is MOTS-c legal?
MOTS-c is not a scheduled or controlled substance, but it is also not FDA-approved for any human therapeutic use — it exists only as a research compound (no IND, no approved indication), consistent with the Level V evidence designation on this page. Compounded research sources are not GMP-manufactured for human use, and purity varies across suppliers. Anyone considering research-compound use should raise it with a licensed physician who can review individual health context and applicable regulations first.
Is MOTS-c FDA-approved?
No. As of 2026, MOTS-c has no FDA-approved indication and no completed, published Phase I, II, or III human clinical trial. The evidence base is Level V (preclinical), drawn from cell-culture and rodent studies plus human observational data on endogenous MOTS-c levels — not from interventional human trials of exogenous MOTS-c.
What does research show about MOTS-c's metabolic and mitochondrial effects?
In preclinical rodent models, exogenous MOTS-c activated AMPK (~2.5-fold increase in phosphorylation), increased skeletal-muscle GLUT4-mediated glucose uptake, enhanced fatty-acid oxidation, and improved insulin sensitivity — HOMA-IR improved roughly 38% in high-fat-diet mice in the original Lee et al. 2015 Cell Metabolism study. Human evidence is limited to observational cohorts showing that lower circulating MOTS-c correlates with worse insulin sensitivity and that levels rise sharply after aerobic exercise — associative findings, not proof of effect from an intervention in people.
What is the human clinical trial status of MOTS-c?
No completed or published human Phase I, II, or III trial of exogenous MOTS-c exists as of 2026. Available human evidence is limited to Level IIb observational studies correlating endogenous plasma MOTS-c with insulin sensitivity, exercise response, and menopausal status. A small Phase I pilot study is reportedly underway in Shanghai but has not yet published results, so human dosing, pharmacokinetics, and efficacy remain unestablished.
What are the safety concerns with MOTS-c?
Rodent studies to date have not shown hepatotoxicity, hypoglycemia, or cardiovascular changes, but those studies ran only 12–16 weeks, so long-term human safety is entirely unknown. Because AMPK plays context-dependent roles in cancer biology, chronic MOTS-c use in the presence of active malignancy is a theoretical, unstudied concern. Compounded research-grade MOTS-c also varies widely in purity and endotoxin levels. These are open questions a physician should weigh against an individual's full health history before any research-compound use is considered — this page does not provide dosing guidance.
How does MOTS-c compare to other metabolic-research peptides on PeptideReport.ai?
MOTS-c is the only compound in the comparator table above that is an endogenous, mitochondria-encoded signal rather than a synthetic analog, activating AMPK indirectly through the folate cycle while also translocating to the nucleus to co-activate FOXO1 and Nrf2. It sits at Level V evidence alongside its sister mitokine Humanin, while Tesamorelin and Metformin carry Level I, FDA-approved human evidence through different mechanisms (the GH axis and Complex I, respectively), and AOD-9604 sits at Level IIb via a distinct fat-specific lipolysis pathway.
SD
Dr. Scott DelBoccio, DMD
Founder, PeptideReport.ai · Physician-Authored Research Platform

Dr. Scott DelBoccio, DMD is a retired dentist with thirty years of clinical practice — including a hormone-therapy and regenerative wellness practice built around individual bloodwork, national lecturing on advanced dental and surgical techniques, mentoring new dentists on practice management, and innovating dental and laser procedures now used throughout North America — who is now heavily involved in peptide research and development, building beginner-to-advanced optimization frameworks calibrated to the individual, and holds workshops and lectures on peptide therapeutics for other clinicians and researchers. PeptideReport.ai synthesizes preclinical literature, endogenous physiology, and mechanistic pharmacology into clinician-accessible reference content for peptide research compounds. MOTS-c is a Level V (preclinical) compound. Nothing on this page constitutes prescribing guidance, a clinical recommendation, or a patient-provider relationship. This page is for educational and scientific awareness purposes only.